Published in Arch Immunol Ther Exp (Warsz) on February 09, 2010
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes. Mol Ther (2012) 1.12
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum (2011) 1.08
Lentiviral gene transfer into the dorsal root ganglion of adult rats. Mol Pain (2011) 1.03
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther (2012) 0.99
Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. Int J Hypertens (2010) 0.95
A high-throughput platform for lentiviral overexpression screening of the human ORFeome. PLoS One (2011) 0.94
Lentiviral vectors for cancer immunotherapy and clinical applications. Cancers (Basel) (2013) 0.93
Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet (2011) 0.92
Development of an all-in-one lentiviral vector system based on the original TetR for the easy generation of Tet-ON cell lines. PLoS One (2011) 0.92
Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PLoS One (2012) 0.89
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85
Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice. PLoS One (2012) 0.85
MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. Immunol Endocr Metab Agents Med Chem (2012) 0.84
Targeting of human antigen-presenting cell subsets. J Virol (2013) 0.83
Comparison of the efficacy of four viral vectors for transducing hypothalamic magnocellular neurosecretory neurons in the rat supraoptic nucleus. J Neurosci Methods (2011) 0.82
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology (2014) 0.82
Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer. World J Gastroenterol (2011) 0.81
Retroviral and lentiviral vectors for the induction of immunological tolerance. Scientifica (Cairo) (2012) 0.80
A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses. Vaccine (2012) 0.79
Gene therapy: a potential approach for cancer pain. Pain Res Treat (2011) 0.78
On the Mechanism of T cell receptor down-modulation and its physiological significance. J Biosci Med (2011) 0.78
DNA vaccination for prostate cancer: key concepts and considerations. Cancer Nanotechnol (2015) 0.78
Generation of a genome scale lentiviral vector library for EF1α promoter-driven expression of human ORFs and identification of human genes affecting viral titer. PLoS One (2012) 0.78
Multifunctional spider silk polymers for gene delivery to human mesenchymal stem cells. J Biomed Mater Res B Appl Biomater (2014) 0.77
Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity. Mol Ther (2017) 0.77
Cleavage of hemagglutinin-bearing lentiviral pseudotypes and their use in the study of influenza virus persistence. PLoS One (2014) 0.75
Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts. J Vis Exp (2016) 0.75
An overview of viral and nonviral delivery systems for microRNA. Int J Pharm Investig (2015) 0.75
Restoration of Thymus Function with Bioengineered Thymus Organoids. Curr Stem Cell Rep (2016) 0.75
Exosomes as nanocarriers for siRNA delivery: paradigms and challenges. Arch Med Sci (2016) 0.75
DNA methylation and histone modifications are the molecular lock in lentivirally transduced hematopoietic progenitor cells. Biomed Res Int (2015) 0.75
Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells. Mol Ther Methods Clin Dev (2017) 0.75
Generation of diverse neural cell types through direct conversion. World J Stem Cells (2016) 0.75
Long-Term Safety Follow-Up of Subjects Previously Treated with Non-Replicating Retroviral Vector-Based Gene Therapies. Mol Diagn Ther (2016) 0.75
Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease. Yale J Biol Med (2016) 0.75
Lentivirus-mediated short hairpin RNA interference targeting TNF-alpha in macrophages inhibits particle-induced inflammation and osteolysis in vitro and in vivo. BMC Musculoskelet Disord (2016) 0.75
The sequence of the human genome. Science (2001) 101.55
Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature (1953) 47.27
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell (1983) 25.46
Viable offspring derived from fetal and adult mammalian cells. Nature (1997) 22.46
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
Genetical implications of the structure of deoxyribonucleic acid. Nature (1953) 16.01
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol (1997) 12.11
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 10.40
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
Synthesis of rabbit beta-globin in cultured monkey kidney cells following infection with a SV40 beta-globin recombinant genome. Nature (1979) 9.99
Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 9.23
Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A (1993) 9.17
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol (1994) 6.60
Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5' long terminal repeat and the start of the gag gene. Proc Natl Acad Sci U S A (1982) 5.56
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet (2004) 5.43
Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol (2007) 5.36
Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol (1999) 5.35
The retroviral enzymes. Annu Rev Biochem (1994) 4.21
Rabbit beta-globin mRNA production in mouse L cells transformed with cloned rabbit beta-globin chromosomal DNA. Nature (1979) 3.88
Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature (1980) 3.78
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol (2004) 3.48
Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A (1997) 3.40
A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J Virol (1992) 3.39
Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol (1997) 3.37
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol (1998) 3.09
A versatile tool for conditional gene expression and knockdown. Nat Methods (2006) 2.92
Effective gene therapy with nonintegrating lentiviral vectors. Nat Med (2006) 2.70
Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther (2009) 2.56
SV40 recombinants carrying rabbit beta-globin gene coding sequences. Cell (1979) 2.35
Targeted cell entry of lentiviral vectors. Mol Ther (2008) 2.34
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood (2007) 2.28
Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy. J Virol (1999) 2.15
Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med (2005) 1.93
Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther (2007) 1.81
Gene therapy for human genetic disease? Science (1972) 1.79
Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood (1995) 1.79
Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A (2006) 1.74
Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood (2009) 1.73
In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood (2007) 1.69
Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol (2004) 1.66
A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med (2008) 1.65
Plus-strand priming by Moloney murine leukemia virus. The sequence features important for cleavage by RNase H. J Mol Biol (1989) 1.65
Targeted genome modifications using integrase-deficient lentiviral vectors. Mol Ther (2007) 1.60
Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med (2003) 1.59
Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet (1993) 1.51
Targeting dendritic cell signaling to regulate the response to immunization. Blood (2008) 1.50
Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood (1994) 1.45
Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A (2006) 1.42
Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther (2002) 1.41
Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther (2005) 1.38
Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol (2008) 1.35
Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood (2002) 1.33
Development of multigene and regulated lentivirus vectors. J Virol (2000) 1.30
Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther (2006) 1.30
Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther (2005) 1.30
Targeted transgene expression in muller glia of normal and diseased retinas using lentiviral vectors. Invest Ophthalmol Vis Sci (2007) 1.28
Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum Gene Ther (2004) 1.27
Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther (2007) 1.27
Dual-promoter lentiviral vectors for constitutive and regulated gene expression in neurons. J Neurosci Methods (2007) 1.25
Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood (2005) 1.24
Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol (2009) 1.24
CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. Gene Ther (2004) 1.23
In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther (2003) 1.22
Viral vectors: from virology to transgene expression. Br J Pharmacol (2009) 1.19
High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood (2001) 1.19
The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. Hum Gene Ther (1990) 1.19
Viral vectors based on bidirectional cell-specific mammalian promoters and transcriptional amplification strategy for use in vitro and in vivo. BMC Biotechnol (2008) 1.16
Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther (2009) 1.15
A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther (2007) 1.13
Identification of ligands and coligands for the ecdysone-regulated gene switch. Proc Natl Acad Sci U S A (2000) 1.13
A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther (2001) 1.12
Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res (2006) 1.12
Pneumocystis pneumonia--Los Angeles. 1981. Am J Public Health (2006) 1.12
Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther (2008) 1.11
Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Inductions of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med (1979) 1.11
A comparative analysis of constitutive and cell-specific promoters in the adult mouse hippocampus using lentivirus vector-mediated gene transfer. J Gene Med (2008) 1.09
Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther (2009) 1.07
Kinetics of retrovirus production and decay. Biotechnol Bioeng (1999) 1.06
Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol (2007) 1.06
Historical study: Johann Gregor Mendel 1822-1884. Am J Med Genet (1991) 1.04
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood (2006) 1.04
Gene therapy in the CNS. Gene Ther (2000) 1.04
Gene transfer into the central nervous system in vivo using a recombinanat lentivirus vector. J Neurosci Res (2002) 1.03
Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther (2007) 1.02
Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging (2008) 1.46
Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol (2008) 1.29
Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother (2007) 1.26
Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res (2012) 1.20
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res (2012) 1.18
Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol (2004) 1.16
CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol (2007) 1.15
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum (2011) 1.08
Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. J Clin Invest (2010) 1.06
Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging. PLoS One (2012) 1.00
Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol Ther (2004) 0.98
Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol (2007) 0.97
Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Res (2012) 0.93
mRNA-based dendritic cell vaccines. Expert Rev Vaccines (2014) 0.93
Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods (2002) 0.93
Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. J Immunol (2013) 0.89
The ReNAissanCe of mRNA-based cancer therapy. Expert Rev Vaccines (2014) 0.88
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunol Immunother (2014) 0.88
Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. Vaccine (2008) 0.87
Immunogenicity of targeted lentivectors. Oncotarget (2014) 0.86
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. Mol Ther Nucleic Acids (2013) 0.86
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. PLoS One (2013) 0.86
PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal. J Clin Cell Immunol (2012) 0.85
MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. Immunol Endocr Metab Agents Med Chem (2012) 0.84
Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells? Oncoimmunology (2013) 0.83
Immune modulation by genetic modification of dendritic cells with lentiviral vectors. Virus Res (2013) 0.83
Targeting of human antigen-presenting cell subsets. J Virol (2013) 0.83
Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. Anticancer Agents Med Chem (2012) 0.81
Variegation and silencing in a lentiviral-based murine transgenic model. Transgenic Res (2009) 0.81
mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother (2013) 0.80
Targeting lentiviral vectors for cancer immunotherapy. Curr Cancer Ther Rev (2011) 0.80
Retroviral and lentiviral vectors for the induction of immunological tolerance. Scientifica (Cairo) (2012) 0.80
The role of SMAC mimetics in regulation of tumor cell death and immunity. Oncoimmunology (2012) 0.77
mRNA: delivering an antitumor message? Immunotherapy (2011) 0.77
Contribution of Cardiac Sodium Channel β-Subunit Variants to Brugada Syndrome. Circ J (2015) 0.75
Adult-Derived Human Liver Stem/Progenitor Cells Infused 3 Days Postsurgery Improve Liver Regeneration in a Mouse Model of Extended Hepatectomy. Cell Transplant (2016) 0.75